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Approaches
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Jinseub Hwang  2, Boyoung Joung  3 & Gregory Y. H. Lip4
The reported incidence and prevalence of atrial fibrillation (AF) has been inconsistent across published 
studies. Using the National Health Insurance Service database of Korea, the prevalence and incidence 
of AF, and oral anticoagulation (OAC) use of AF patients were explored according to three different 
approaches; ‘formal approach’, considering individual AF diagnosis and mortality; ‘limited diagnosis 
approach’, using upper 5 main diagnosis; and ‘medical use approach’, using the number of medical 
use AF population by year without considering individual AF history and mortality. The AF prevalence 
progressively increased by 2.46-fold from 0.50% in 2004 to 1.54% in 2015 when using a ‘formal 
approach’ (p for trend <0.001). The overall prevalence was 1.09% and 0.97% when using a ‘formal 
approach’ and ‘limited diagnosis approaches’, respectively. Overall prevalence decreased to 0.52% with 
a ‘medical use approach’. The trend of annual AF incidence was stable when using a ‘formal approach’, 
but increased by 15% when using a ‘medical use approach’. OAC rate in 2015 was 2.1 times higher when 
using a ‘medical use approach’ compared to using a ‘formal approach’ (40.3% vs. 19.1%, p < 0.001). 
Given the wide variability in prevalence and incidence figures with different analysis approaches, careful 
attention to the analysis methodology is needed.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population1. Due to age-
ing of the general population and the increasing prevalence of risk factors, there has been an increase in the inci-
dence and prevalence of AF2. However, estimates of AF incidence and prevalence differ widely. These variations 
might be attributable to the design and time period of study, and an improved surveillance for AF with increased 
use of diagnostic tools and health care awareness. This study investigated the prevalence and incidence of AF 
population according to different analysis methodological approaches using national insurance data. Second, we 
examined the variation of national oral anticoagulation (OAC) rate of AF population according to the variation 
of prevalence of AF.
Methods
Study population. This nationwide study is based on the national health claims database established by 
the National Health Insurance Service (NHIS) of Korea3. The NHIS is the single insurer managed by the Korean 
government, and the majority (97.1%) of Korean population are mandatory subscribers, with the remaining 3% 
of the population being medical aid subjects. The NHIS database contains the information of medical aid subjects, 
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therefore it is based on the entire Korean population. The following medical information is provided: patients’ 
sociodemographic information, their use of inpatient and outpatient services, pharmacy dispensing claims, and 
mortality data. This study was approved by the Institutional Review Board of Yonsei University Health System 
(4-2016-0179). The IRB waived the requirement to obtain informed consent, and this study was conducted in 
accordance with the tenets of the Declaration of Helsinki.
Definition of atrial fibrillation. AF was diagnosed using the International Classification of Disease 10th 
Revision (ICD-10) codes, I48 (atrial fibrillation and atrial flutter), I48.0 (atrial fibrillation), and I48.1 (atrial flut-
ter). We regarded first date of getting AF-related ICD-10 codes as the newly diagnosed year, and excluded first 2 
years (2002 to 2003) to avoid the possibility for misdiagnosis of preexisting AF for incident AF. Moreover, patients 
were defined as AF only when it was a discharge diagnosis or confirmed at least twice in the outpatient depart-
ment to ensure diagnostic accuracy. The AF diagnosis has previously been validated with a positive predictive 
value of 94.1%4,5. We excluded patients <20 years, patients with valvular AF. Valvular AF was defined from a 
diagnosis of mitral stenosis (ICD-10: I05.0, I05.2, and I34.2) or prosthetic heart valve (ICD-10: Z95.2–Z95.4), and 
insurance claims for valve replacement or valvuloplasty.
Definition of comorbidities. Comorbidities were defined using the medical claims according to ICD-10 
codes and prescription medication use. In order to ensure diagnostic accuracy, we defined patients with comor-
bidities (including previous stroke, previous transient ischaemic attack, heart failure, hypertension, diabetes, 
previous myocardial infarction, peripheral arterial disease, dyslipidemia) when it was a discharge diagnosis or 
was confirmed at least twice in an outpatient setting, which was similar to previous studies with NHIS4–9. The 
definitions of comorbidities are presented in Supplementary Table S1.
Methodological approaches. We evaluated three different methodological approaches to evaluate the 
prevalence and incidence of AF; ‘formal approach’, ‘limited diagnosis approach’, and ‘medical use approach’. (1) 
In the ‘formal approach’, we considered individual AF diagnosis history and mortality. The annual prevalence of 
AF was calculated by dividing the number of AF patients of each year with exception for AF patients who died in 
previous year by the number of total Korean residents of that year. The annual incidence of AF was the number of 
incident cases of AF divided by the number of person-years at risk among all Korean residents of that year who 
had never been diagnosed as AF. Supplementary Table S2 shows the number and distribution of total Korean res-
idents aged ≥20 years. (2) In the ‘limited diagnosis approach’, we included patients with an AF diagnosis within 
5 main diagnosis fields during whole follow up period. The other conditions were the same as in the ‘formal 
approach’. (3) In the ‘medical use approach’, we used the number of AF patients who claimed medical expenses 
by year without considering individual AF history and mortality. We calculated the annual prevalence of AF by 
the number of AF patients who claimed medical expenses in each year divided by the number of total Korean 
residents of that year. The incident AF of each year was calculated using an increase in the number of AF patients 
who claimed medical expenses as compared to the previous year. The annual incidence of AF was the number of 
incident AF divided by the number of Korean residents of that year. The OAC rate was also calculated based on 
prevalence by the three different approaches.
Statistical analysis. Data are presented as mean value ± standard deviation for continuous variables and 
proportions for categorical variables. The Cochran-Armitage trend test was used for analyzing temporal trends 
of categorical variables. The nonparametric test for trend by Jonckheere-Terpstra was used for continuous varia-
bles. All tests were two-tailed, with P < 0.05 considered significant. Statistical analyses were conducted with SAS 
version 9.4 (SAS Institute, Cary, NC, USA), R version 3.4.1, and SPSS version 23.0 statistical package (SPSS Inc., 
Chicago, IL, USA).
Data availability. The data that support the findings of this study are available from the NHIS, but restric-
tions apply to the availability of these data, which were used under license for the current study, and so are not 
publicly available. Data are however available from the authors upon reasonable request and with permission of 
the NHIS.
Results
Between January 1, 2004 and December 31, 2015, the ‘formal approach’ identified 802,503 patients with newly 
diagnosed AF. The mean age was 64.9 ± 14.9 years, and 52.9% were men. Table 1 shows temporal trends in demo-
graphics and comorbidities of patient with AF.
Figure 1A shows the annual prevalence of AF between 2004 and 2015. The prevalence progressively increased 
by 2.46-fold from 0.50% in 2004 to 1.54% in 2015 when using a ‘formal approach’ (p for trend <0.001). The 
overall prevalence of AF was 1.09% and 0.97% when using a ‘formal approach’ and a ‘limited diagnosis approach’, 
respectively. When using a ‘medical use approach’, the overall prevalence was decreased to 0.52%, although the 
annual prevalence still gradually increased (p for trend <0.001). Figure 1B shows the annual incidence of AF 
between 2004 and 2015. During the study period of 12-years, the incidence did not change significantly with the 
incidence of 1.68 in 2004 and 1.73 per 1,000 person-years in 2015 when using a ‘formal approach’. The incidence 
dramatically increased from 1.7 in 2004 to 2.0 per 1,000 person-years in 2015 when using a ‘medical use approach’ 
(p for trend <0.001).
Figure 2 shows OAC rates according to different analysis approaches in overall AF population. The rates of 
OAC use at the last year (in 2015) were 19.1%, 21.3% and 40.3% in overall AF population when using ‘formal 
approach’, ‘limited diagnosis approach’, and ‘medical use approach’, respectively. The rate of OAC use in 2015 was 
2.1 times higher when using the ‘medical use approach’ compared to using the ‘formal approach’ (p < 0.001).
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Discussion
In this study, the prevalence and incidence of AF changed dramatically by three different analysis approaches. The 
‘formal approach’ showed a progressive increase of prevalence and stable incidence. The ‘medical use approach’ 
showed progressive increase of both prevalence and incidence. The overall prevalence of ‘medical use approach’ 
was only half of that with the ‘formal approach’. The ‘formal approach’ was used in most of the recent studies about 
the AF epidemiology, including nationwide cohort based studies from Taiwan and Korea8,10. On the other hand, 
Lee et al. used the ‘medical use approach’ to investigate the incidence and prevalence of AF in Korea11,12.
The prevalence of AF calculated using ‘formal approach’ in our study was similar to the recent prevalence 
rates ranging from 1.07% to 1.6% in Asia (1.07% in Taiwan10, 1.38% in Korea8, 1.5% in Singapore13, and 1.6% in 
Japan14). Therefore, the prevalence using ‘medical use approach’, which is half of that with the ‘formal approach’, is 
likely to be underestimated, and not to reflect the actual prevalence.
The overall AF incidence of Korean was around 1.70 per 1,000 person-years using the ‘formal approach’ which 
was similar with the recently reported incidence of Taiwan of 1.51 per 1,000 person-years10, and was lower com-
pared to that seen in Caucasians2,15,16. Using the ‘formal’ and ‘limited diagnosis approach’, the annual trends of AF 
incidence were stable similarly with the recent Taiwan study, but were clearly increased when using the ‘medical 
use approach’10.
Using national insurance data, which includes information on the medical use of entire citizens, it is pos-
sible to study various national medical indicators. However, depending on how the data is analysed, the basic 
Overall 2004–2015
(n = 802,503)
2004–2007
(n = 258,638)
2008–2011
(n = 265,386)
2012–2015
(n = 278,479) p-value
Age (years) 64.9 ± 14.9 63.0 ± 14.9 64.8 ± 14.9 66.9 ± 14.6 <0.001
Male 52.9 52.1 52.6 53.9 <0.001
Comorbidity
 Previous stroke 16.9 11.7 17.4 21.2 <0.001
 Previous TIA 6.7 3.8 7.2 9.0 <0.001
 Heart failure 21.3 18.2 21.0 24.3 <0.001
 Hypertension 65.5 57.1 66.8 71.9 <0.001
 Diabetes mellitus 20.6 17.1 20.9 23.7 <0.001
 Previous MI 7.3 6.1 7.5 8.3 <0.001
 PAD 9.4 4.3 9.5 13.9 <0.001
 Dyslipidemia 47.4 29.0 47.8 64.0 <0.001
CHA2DS2-VASc score 2.96 ± 2.10 2.53 ± 1.87 2.99 ± 2.09 3.34 ± 2.22 <0.001
Table 1. Baseline characteristics of incident AF between 2004 and 2015. AF; atrial fibrillation; TIA, transient 
ischaemic attack; MI, myocardial infarction; PAD, peripheral artery disease. Values are presented as % or 
mean ± SD.
Figure 1. Annual prevalence (A) and incidence (B) of atrial fibrillation between 2004 and 2015 according to 
different analysis approaches.
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epidemiology indicators such as prevalence and incidence may also vary as we have shown in this study. If prev-
alence is miscalculated, other important medical indicators will be misjudged accordingly. In our results, the 
national rate of OAC use in AF patients differed by more than two-fold depending on the method we used to 
calculate the prevalence. A careful approach is needed when conducting this kind of research.
Study limitations. There are several limitations in this study, given the natures of the nationwide registry 
dataset we used. Although administrative databases are increasingly used for clinical research, such studies are 
potentially susceptible to errors arising from coding inaccuracies. To minimize this problem, we examined the 
nationwide cohort, and applied the definition that we already validated in previous studies that used a Korean 
NHIS sample cohort4,5,9,17. Since we defined AF cases only with ICD-10 codes, it is possible that either paroxysmal 
or asymptomatic AF cases, which were not ascertained by these codes, were not recorded.
Conclusions
The reported incidence and prevalence of AF varies widely when using different analysis approaches. Compared 
with the ‘formal approach’, the ‘medical use approach’ showed an increasing trend of incidence, half the preva-
lence of AF, and twofold higher OAC use. Given the wide variability in prevalence and incidence figures with 
different analysis approaches, careful attention to the analysis methodology is needed.
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